---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Avapritinib - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/avapritinib
version: v1
---

# Avapritinib - NCI

# Avapritinib

Placeholder slot

(AY-vah-PRIH-tih-nib)

This page contains brief information about avapritinib and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Ayvakit

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9&audience=consumer)

## Use in Cancer

Avapritinib
is approved to treat adults with:

- **[Gastrointestinal stromal tumor](/Common/PopUps/popDefinition.aspx?id=44998&version=Patient&language=English)** (GIST) that cannot be removed by surgery or has [metastasized](/Common/PopUps/popDefinition.aspx?id=46283&version=Patient&language=English) (spread to other parts of the body) and has certain [mutations](/Common/PopUps/popDefinition.aspx?id=46063&version=Patient&language=English) in the *[PDGFRA](/Common/PopUps/popDefinition.aspx?id=800549&version=Patient&language=English)* gene.
- **[Systemic mastocytosis](/Common/PopUps/popDefinition.aspx?id=455141&version=Patient&language=English)** that is [advanced](/Common/PopUps/popDefinition.aspx?id=478743&version=Patient&language=English), including the following types:
- [Aggressive](/Common/PopUps/popDefinition.aspx?id=789073&version=Patient&language=English) systemic mastocytosis.
- Systemic
mastocytosis with an associated [hematologic neoplasm](/Common/PopUps/popDefinition.aspx?id=45708&version=Patient&language=English) (SM-AHN).
- [Mast cell leukemia](/Common/PopUps/popDefinition.aspx?id=789079&version=Patient&language=English).

Avapritinib is not recommended for the treatment of advanced systemic mastocytosis in people with low platelet
counts (less than 50 Ã— 109/L).

Avapritinib
is also being studied in the treatment of other conditions and other types of
cancer.

## More About Avapritinib

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/775630) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Avapritinib](https://medlineplus.gov/druginfo/meds/a620013.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Avapritinib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C123827) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
